[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Stereotaxis Inc (STXS)

Stereotaxis Inc (STXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 181,309
  • Shares Outstanding, K 97,478
  • Annual Sales, $ 32,380 K
  • Annual Income, $ -21,640 K
  • EBIT $ -22 M
  • EBITDA $ -21 M
  • 60-Month Beta 1.43
  • Price/Sales 5.81
  • Price/Cash Flow N/A
  • Price/Book 13.36

Options Overview Details

View History
  • Implied Volatility 189.50% (+7.09%)
  • Historical Volatility 42.20%
  • IV Percentile 92%
  • IV Rank 39.60%
  • IV High 404.93% on 03/09/26
  • IV Low 48.26% on 08/11/25
  • Expected Move (DTE 16) 0.5015 (28.02%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 47
  • Volume Avg (30-Day) 48
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 5,810
  • Open Int (30-Day) 5,572
  • Expected Range 1.2885 to 2.2915

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 2
  • High Estimate $-0.04
  • Low Estimate $-0.05
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7600 +1.71%
on 03/30/26
2.1200 -15.56%
on 04/17/26
-0.0299 (-1.64%)
since 03/27/26
3-Month
1.7400 +2.88%
on 03/19/26
2.3450 -23.66%
on 03/05/26
-0.5399 (-23.17%)
since 01/29/26
52-Week
1.7400 +2.88%
on 03/19/26
3.5900 -50.14%
on 10/09/25
-0.2299 (-11.38%)
since 04/29/25

Most Recent Stories

More News
Stereotaxis Announces First MAGiC Procedures in the United States

ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients...

STXS : 1.7800 (-4.30%)
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will...

STXS : 1.7800 (-4.30%)
Stereotaxis Announces Definitive Agreement to Acquire Robocath

ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced...

STXS : 1.7800 (-4.30%)
Stereotaxis Announces FDA Clearance and Launch of Synchrony System

ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has...

STXS : 1.7800 (-4.30%)
Stereotaxis Reports 2025 Full Year Financial Results

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results...

STXS : 1.7800 (-4.30%)
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will...

STXS : 1.7800 (-4.30%)
Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of...

STXS : 1.7800 (-4.30%)
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S....

STXS : 1.7800 (-4.30%)
Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company...

STXS : 1.7800 (-4.30%)
Stereotaxis Reports 2025 Third Quarter Financial Results

ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results...

STXS : 1.7800 (-4.30%)

Business Summary

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters, guidewires...

See More

Key Turning Points

3rd Resistance Point 2.0217
2nd Resistance Point 1.9833
1st Resistance Point 1.9217
Last Price 1.7800
1st Support Level 1.8217
2nd Support Level 1.7833
3rd Support Level 1.7217

See More

52-Week High 3.5900
Fibonacci 61.8% 2.8833
Fibonacci 50% 2.6650
Fibonacci 38.2% 2.4467
Last Price 1.7800
52-Week Low 1.7400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.